Investor Presentaiton
Strategic Alliance Highlights
*
Already launched
Partner
Product
Indications
Region Launch Year(E)
Remarks
Genovate
Entecavir
Hepatitis B Virus Taiwan
2013*
1st co-developed formulation product launch
Sagent
Oncology
Injectable
Myeloid
Leukemia
US
2018
1st US ANDA filing, triggering US FDA inspection
in Changshu, China site
Foresee
Leuprolide
Prostate cancer
US
2019
505(b)(2) NDA CRAM + Equity
Coland
Bortezomib
Multiple
China
2020
Myeloma
1st co-developed drug in China to trigger CFDA
inspection in Changshu site
Fondaparinux Anti-thrombotic China
2022
Lee's
Co-development collaboration
Pharma
Travoprost
Glaucoma
China
2022
&Bimatoprost
Nanjing
King Friend
Stress agent for
Regadenoson
China
2021
heart scan
US partner
Project A
Non-small cell
lung cancer
US
2018
US & China
partners
Project B
Imaging agent
US
2021
Co-developed formulation in China
US NDA 505(b)(2) / The estimated launch year
is subject to litigation results
ANDA with Paragraph IV filing/
The estimated launch year is subject to
litigation results
Baxter
ā
5 niche
injectables
Anti-cancer &
antinauseant
US/EU
2020&
continuing
thereafter
Baxter has the right to add up to 15 additional
injectable products for collaboration
Indian Int'l
partner
Fondaparinux Anti-thrombotic
US/EU
2018
1st self-developed US ANDA submitted.
Executive right for marketing & sales
27
SeinoPharmView entire presentation